The increase in the price target by UBS analyst Kevin Caliendo for Cardinal Health (CAH) from $122 to $125, while maintaining a Buy rating, suggests a positive outlook on the company's future performance. This adjustment reflects an expectation of upward movement in CAH's stock price in the short term, likely driven by investor optimism following the analyst's updated valuation.